John Lansing's Trending123
John Lansing's Trending123
Username: Password: Login
Trade Talk E-Letter Products & Services Trading Tools Portfolios Members Home
Enter Symbol:
GENZ @ Yahoo Finance
GENZ Option @ Yahoo Finance
Stock Details
Current Price High Value Change Percent Change Dividend Previous Close
$ 73.35 $ 74.04 $ -0.18 -0.24% 0.00 $ 73.53
Opening Price Low Volume Market Cap Average Volume P/E
$ 73.76 $ 72.15 2.03M 19.44B 2.7M 19.87
Pivot Table
R2 R1 Pivot S1 S2
75.07 74.21 73.18 72.32 71.29

stock chart

Genzyme Corporation operates as a biotechnology company. Its products and services focuses on rare genetic disorders, renal disease, kidney disease, cancer, orthopaedics, organ transplant, and diagnostic and predictive testing. The company operates in five segments: Renal, Therapeutics, Transplant, Biosurgery, and Diagnostics/Genetics. The Renal unit develops, manufactures, and distributes products that treat patients suffering from renal diseases, including chronic renal failure. The Therapeutics unit offers therapeutic products for genetic diseases; and other chronic debilitating diseases, including lysosomal storage disorders and other specialty therapeutics. The Transplant unit provides therapeutic products that address pretransplantation, prevention, and treatment of acute rejection in organ transplantation, as well as other auto-immune disorders. The Biosurgery unit develops, manufactures, and distributes biotherapeutics and biomaterial products, with an emphasis on products that meet medical needs in orthopaedics and broader surgical areas. The Diagnostics/Genetics unit offers vitro diagnostic products; and testing services for the oncology, and prenatal and reproductive markets. The company offers its products primarily to physicians, hospitals, and treatment centers in various countries, including the United States, the United Kingdom, Ireland, the Netherlands, Belgium, France, Canada, Switzerland, and Germany. Genzyme Corp. has an agreement with RenaMed Biologics, Inc. to jointly develop and commercialize RenaMed's Bio-Replacement Therapy for the treatment of acute renal failure; a collaboration with De Novo Pharmaceuticals, Ltd. to apply De Novo's molecular structure generating technology to focus on a disease target of interest to Genzyme; and a collaboration agreement with Epiontis GmbH to develop quality control tests for Genzyme's cartilage repair product Carticel. The company was founded in 1981 and is based in Cambridge, Massachusetts.

  • Premarket, intraday, nightly, and weekend updates, which include stock picks with full instructions, market direction (short, intermediate, long term), precious metal, commodity, and currency analysis.
  • Provide you stock picks (breakouts) and market direction to help you become
    more profitable.

  • Voice over chart updates sent to you by e-mail. These updates contain stock picks and market status for a number of different portfolios, which Trending123 is recommending and following.
  • Instantaneous e-mail alerts during the trading day when targets have been hit or the status of a position or the market warrants a move. Stock Recommendations for swing traders, day traders, and long term investors.
  • Receive instant emails to your computer, organizer, cell phone of breakouts on stocks.....Learn More